Joshua D. Hansen

发表

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Ellen R. Laird, Tyler Risom, Zhaoyang Wen, 2011, Bioorganic & medicinal chemistry letters.

Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

L. Hamann, J. Ellis, P. Chamberlain, 2019, ACS medicinal chemistry letters.

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.

E. Laird, S. Gloor, G. Vigers, 2014, Bioorganic & medicinal chemistry letters.

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

L. Hamann, L. LeBrun, B. Cathers, 2020, Journal of medicinal chemistry.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

Total synthesis of (-)-7-epicylindrospermopsin, a toxic metabolite of the freshwater cyanobacterium aphanizomenonovalisporum, and assignment of its absolute configuration.

James D White, Joshua D. Hansen, 2005, The Journal of organic chemistry.

Asymmetric synthesis of epicylindrospermopsin via intramolecular nitrone cycloaddition. Assignment of absolute configuration.

James D White, Joshua D. Hansen, 2002, Journal of the American Chemical Society.

Synthesis of spirolactams and spiropiperidines as CCR4 receptor antagonists

Aaron S. Anderson, E. Laird, D. Chantry, 2006 .

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.

L. LeBrun, B. Cathers, M. Pourdehnad, 2021, Journal of medicinal chemistry.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

Non-oxime pyrazole based inhibitors of B-Raf kinase.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Mike Welch, E. Laird, B. Brandhuber, 2008, Bioorganic & medicinal chemistry letters.

Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists.

Aaron S. Anderson, E. Laird, D. Chantry, 2004, Bioorganic & medicinal chemistry letters.

CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells.

J. Dick, M. Minden, C. Fontanillo, 2020, Blood.

Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

Chin-Chun Lu, L. LeBrun, Alexander L. Ruchelman, 2017, Journal of medicinal chemistry.

Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.

E. Hur, Lisa Morrison, B. Bennett, 2021, Journal of medicinal chemistry.